In adult patients with severe alcoholic hepatitis, what are the indications for therapeutic plasma exchange (plasmapheresis)?

Plasmapheresis (Therapeutic Plasma Exchange) in Severe Alcoholic Hepatitis

Plasmapheresis is NOT a standard or guideline-recommended therapy for severe alcoholic hepatitis and should only be considered as experimental bridge therapy in highly selected patients with very severe disease (MELD >26-30) who are non-responders to standard medical treatment and lack immediate transplant options.

Current Guideline-Based Standard of Care

The established treatment algorithm for severe alcoholic hepatitis does NOT include plasmapheresis as a recommended intervention 1, 2. The AGA Institute and EASL guidelines from 2017-2018 outline the following standard approach:

For Severe Disease (MDF >32 or MELD >20):

• First-line therapy: Prednisolone 40 mg/day or methylprednisolone 32 mg/day for 28 days 1
• Assessment at day 7: Use Lille score to identify non-responders (score ≥0.45, particularly ≥0.56 for "null responders") 2
• For non-responders: Stop corticosteroids and consider early liver transplantation evaluation in highly selected patients with MELD >26 1
• Alternative for steroid contraindications: Pentoxifylline 400 mg three times daily (though efficacy data are conflicting) 1

Critical Supportive Measures:

• Alcohol abstinence (cornerstone of treatment) 1
• Nutritional support: 35-40 kcal/kg body weight and 1.2-1.5 g protein/kg daily 2
• Infection screening and treatment 1
• Avoidance of nephrotoxic drugs 1

Emerging Experimental Role of Plasmapheresis

While NOT guideline-recommended, recent research suggests plasmapheresis may have a role in very severe cases as experimental therapy:

Potential Indications Based on Research Evidence:

Very Severe Alcoholic Hepatitis (VSAH) with:

• MELD score >26-30 3
• Acute-on-chronic liver failure (ACLF) grade II 4
• Non-response to standard medical treatment 4
• No immediate prospects for liver transplantation 4
• Markedly elevated bilirubin and coagulation defects 5

Evidence Supporting Experimental Use:

A 2025 retrospective study showed that centrifugal plasma exchange (cPLEX) combined with low-dose steroids in very severe alcoholic hepatitis improved one-year transplant-free survival to 52.4% versus 16.7% with standard medical treatment alone 3. The study specifically targeted patients with VSAH and ACLF 3.

A 2022 case-control pilot study demonstrated that therapeutic plasma exchange in alcohol-associated ACLF grade II patients who were non-responders to standard treatment resulted in:

• Significant reduction in bilirubin, ammonia, INR, PT, and severity scores 4
• Lower 90-day mortality (though 30-day mortality was not significantly different) 4
• Only 2% procedure-related adverse events 4

Important Caveats and Limitations:

This is NOT standard of care - The evidence consists only of small retrospective analyses and pilot studies, not large randomized controlled trials 3, 4, 5. Major hepatology guidelines do not recommend plasmapheresis for alcoholic hepatitis 1, 2.

Patient selection is critical - The research suggests benefit primarily in:

• Very severe disease (not just "severe") 3
• Patients with ACLF who have failed standard therapy 4
• Those requiring bridge therapy to potential transplantation 4

Technique matters - One study suggested centrifugal plasma exchange may be superior to membrane-based techniques 3.

Combination therapy - The best outcomes were seen when plasma exchange was combined with low-dose corticosteroids (10-20 mg prednisolone daily), not plasma exchange alone 3.

Practical Clinical Algorithm

Step 1: Assess Severity

• Calculate MDF, MELD, ABIC, or Glasgow scores 1
• Screen for infections systematically 1

Step 2: For Severe Disease (MDF >32 or MELD >20)

• Initiate corticosteroids if no contraindications 1
• Provide aggressive nutritional support 2
• Ensure alcohol abstinence 1

Step 3: Assess Response at Day 7

• Calculate Lille score 2
• If Lille ≥0.45 (especially ≥0.56): Stop steroids 2

Step 4: For Non-Responders with MELD >26

• First priority: Evaluate for early liver transplantation 1
• If transplant not immediately available: Consider referral to specialized center for experimental plasma exchange as bridge therapy 3, 4

Step 5: Plasma Exchange Protocol (If Pursued Experimentally)

• Standard volume therapeutic plasma exchange 4
• Average 3-4 procedures per patient 4
• Consider centrifugal technique over membrane-based 3
• Combine with low-dose corticosteroids (10-20 mg prednisolone) 3
• Monitor for procedure-related complications 4

Critical Pitfalls to Avoid

Do not use plasma exchange as first-line therapy - Standard corticosteroids remain the evidence-based first-line treatment for severe alcoholic hepatitis 1, 2.

Do not delay transplant evaluation - For patients with MELD >26 who are steroid non-responders, early transplant evaluation should be the priority, not plasma exchange 1.

Do not ignore contraindications to steroids - Active infection (especially tuberculosis, hepatitis B), uncontrolled gastrointestinal bleeding, and acute kidney injury require stabilization first 1.

Do not neglect supportive care - Regardless of specific therapies, nutritional support, infection prevention, and alcohol abstinence are fundamental 1, 2.